ClinicalTrials.gov Updates Phase 2 Trial Registration for iPSC-Derived Retinal Pigment Epithelium Cell Transplantation for Age-Related Macular Degeneration

August 2, 2026

ClinicalTrials.gov USA

Overview

Information regarding a Phase 2 clinical trial for iPSC-derived Retinal Pigment Epithelium (RPE) cell transplantation targeting Age-related Macular Degeneration (AMD) has been updated or newly registered on ClinicalTrials.gov. This trial aims to evaluate the safety and initial efficacy of the treatment in AMD patients. This update signals steady clinical progression in developing eye disease treatments using iPSC technology, offering new hope to patients.

In Depth

Key Findings

Information concerning a Phase 2 clinical trial for iPSC-derived Retinal Pigment Epithelium (RPE) cell transplantation, targeting Age-related Macular Degeneration (AMD), has either been updated or newly registered on ClinicalTrials.gov. This development indicates the steady progression of iPSC-based ophthalmological regenerative medicine into the next clinical phase.

Technical / Clinical Details

In this Phase 2 clinical trial, the safety profile and initial efficacy, specifically improvements in visual acuity and stabilization of disease progression, of the iPSC-derived RPE cell transplantation therapy—already confirmed for safety in Phase 1—will be evaluated in a larger patient cohort. RPE cells play a critical role in supporting retinal photoreceptor cells, and their damage in AMD leads to vision loss. Transplanting iPSC-derived RPE cells aims to replenish damaged RPE cells and normalize the retinal environment, thereby restoring or preserving visual function. The trial is expected to be conducted across multiple centers, enrolling dozens of patients. Key endpoints are anticipated to include visual acuity (best-corrected visual acuity), changes in retinal structure (assessed by optical coherence tomography), and the incidence of adverse events.

Background & Context

Age-related Macular Degeneration is a leading cause of adult blindness in developed countries, with particularly limited effective treatments for progressive atrophic AMD (dry AMD). iPSC-derived RPE cell transplantation is highly anticipated as a groundbreaking treatment option for this intractable disease because it directly replenishes lost cells and addresses the root cause of the condition. Previous Phase 1 trials confirmed the safety of iPSC-derived RPE cell transplantation, with some patients showing signs of visual improvement, underscoring the promise of this therapy as it moves into Phase 2.

Strategic Significance & Outlook

The success of the Phase 2 clinical trial would significantly increase the potential for iPSC-derived RPE cell transplantation therapy to become a new standard of care for AMD. Data on safety and efficacy gathered from this trial will form a crucial basis for future large-scale clinical trials and regulatory approval applications. If approved, this therapy is expected to offer millions of patients suffering from dry AMD unprecedented hope for vision recovery and improved quality of life. Furthermore, this achievement will likely stimulate research and development in applying iPSC technology to other neurodegenerative diseases and organ regeneration.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.